PureTech's Commerse Business Makes Progress With Microbiome Studies

LONDON (Alliance News) - Healthcare company PureTech Health PLC on Thursday said its Commense business has expanded its pipeline of therapeutics and signed an exclusive licence in the microbiome field.

PureTech said Commerse, which looks to prevent and treat disease through microbiome-based interventions in infancy and early childhood, had made progress in its studies, with the expansion of its pipeline of microbial-derived therapeutics, supported by its platform which characterises and designs microbiome-based therapeutics to potentially restore these "missing microbes". PureTech did not say what this expansion involved.

PureTech added the company has also obtained a worldwide licence from New York University "on a key building block of its platform", which replenishes and bolsters the microbial exposure that a baby experiences at birth.

"We are excited to build on our knowledge and network of experts in the microbiome field. Commense is developing new microbial-derived therapies targeting the formative years of life, a time when the microbiome plays a crucial role," said PureTech Chief Executive Daphne Zohar.

Shares in PureTech were down 1.2% at 147.15 pence on Thursday.

By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland

Copyright 2016 Alliance News Limited. All Rights Reserved.

PureTech